Polymers in Oral Modified Release Systems

Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice

Volumn , Issue , 2010, Pages 71-87

  Tu, Jiasheng ^a   Shen, Yan ^a   Mahalingam, Ravichandran ^b   Jasti, Bhaskara ^c   Li, Xiaoling ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Formurex Inc   (United Kingdom)

^c UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Bioadhesive controlled release system polymers; Hydroxypropyl methylcellulose (HPMC) application in oral controlled release systems; Polymers in oral modified release systems

Indexed keywords

EID: 84859586135     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470640487.ch5     Document Type: Chapter

References (111)

1. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan-a review. J. Control. Release 2006;114(1):1-14.
2. Aiedeh K, Taha MO. Synthesis of iron-crosslinked chitosan succinate and iron-crosslinked hydroxamated chitosan succinate and their in vitro evaluation as potential matrix materials for oral theophylline sustained-release beads. Eur. J. Pharm. Sci. 2001;13(2):159-168.
3. Atyabi F, Majzoob S, Dorkoosh F, Sayyah M, Ponchel G. The impact of trimethyl chitosan on in vitro mucoadhesive properties of pectinate beads along different sections of gastrointestinal tract. Drug Dev. Ind. Pharm. 2007;33(3):291-300.
4. Chandy T, Rao GH, Wilson RF, Das GS. Delivery of LMW heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis. Drug Deliv. 2002;9(2):87-96.
5. Iruin A, Fernandez-Arevalo M, Alvarez-Fuentes J, Fini A, Holgado MA. Elaboration and ?in vitro? characterization of 5-ASA beads. Drug Dev. Ind. Pharm. 2005;31(2): 231-239.
6. Lin YH, Liang HF, Chung CK, Chen MC, Sung HW. Physically crosslinked alginate/N,O-carboxymethyl chitosan hydrogels with calcium for oral delivery of protein drugs. Biomaterials 2005;26(14):2105-2113.
7. Onal S, Zihnioglu F. Encapsulation of insulin in chitosancoated alginate beads: oral therapeutic peptide delivery. Artif. Cells blood Substit. Immobil. Biotechnol. 2002; 30(3):229-237.
8. Rajinikanth PS, Mishra B. Preparation and in vitro characterization of gellan based floating beads of acetohydroxamic acid for eradication of H. pylori. Acta Pharm. (Zagreb, Croatia) 2007;57(4):413-427.
9. Andersson M, Lofroth JE. Small particles of a heparin/chitosan complex prepared from a pharmaceutically acceptable microemulsion. Int. J. Pharm. 2003;257(1-2):305-309.
10. Cano-Cebrian MJ, Zornoza T, Granero L, Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr. Drug Deliv. 2005;2(1):9-22.
11. Foger F, Kafedjiiski K, Hoyer H, Loretz B, Bernkop-Schnurch A. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. J. Drug Target. 2007; 15(2):132-139.
12. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 2005; 25(1):133-143.
13. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. pHsensitive microsphere delivery increases oral bioavailability of calcitonin. J. Control. Release 2004;98(1):1-9.
14. Maestrelli F, Zerrouk N, Chemtob C, Mura P. Influence of chitosan and its glutamate and hydrochloride salts on naproxen dissolution rate and permeation across Caco-2 cells. Int. J. Pharm. 2004;271(1-2):257-267.
15. Martien R, Loretz B, Schnurch AB. Oral gene delivery: design of polymeric carrier systems shielding toward intestinal enzymatic attack. Biopolymers 2006;83(4):327-336.
16. Martin L, Wilson CG, Koosha F, Uchegbu IF. Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels. Eur. J. Pharm. Biopharm. 2003;55(1):35-45.
17. Palmberger TF, Hombach J, Bernkop-Schnurch A. Thiolated chitosan: development and in vitro evaluation of an oral delivery system for acyclovir. Int. Pharm. 2008;348(1-2): 54-60.
18. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Alonso MJ. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J. Control. Release 2006;111(3):299-308.
19. Raiman J,TormalehtoS, Yritys K,JungingerHE,MonkkonenJ. Effects of various absorption enhancers on transport of clodro- REFERENCES 83 nate through Caco-2 cells. Int. J. Pharm. 2003;261(1-2): 129-136.
20. Ross BP, Toth I. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr. Drug Deliv. 2005;2(3):277-287.
21. Shah P, Jogani V, Mishra P, Mishra AK, Bagchi T, Misra A. Modulation of ganciclovir intestinal absorption in presence of absorption enhancers. J. Pharm. Sci. 2007;96(10): 2710-2722.
22. Thanou M, Henderson S,Kydonieus A, Elson C. N-Sulfonato- N,O-carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromolecules. J. Control. Release 2007;117(2):171-178.
23. van der Merwe SM, Verhoef JC, Kotze AF, Junginger HE. N-Trimethyl chitosan chloride as absorption enhancer in oral peptide drug delivery. Development and characterization of minitablet and granule formulations. Eur. J. Pharm. Biopharm. 2004;57(1):85-91.
24. Bernkop-Schnurch A, Pinter Y, Guggi D, Kahlbacher H, Schoffmann G, Schuh M, et al. The use of thiolated polymers as carrier matrix in oral peptide delivery-proof of concept. J. Control. Release 2005;106(1-2):26-33.
25. Bernkop-Schnurch A, Schuhbauer H, Clausen AE, Hanel R. Development of a sustained release dosage form for alphalipoic acid. I. Design and in vitro evaluation. Drug Dev. Ind. Pharm. 2004;30(1):27-34.
26. Di Colo G, Baggiani A, Zambito Y, Mollica G, Geppi M, Serafini MF. A new hydrogel for the extended and complete prednisolone release in the GI tract. Int. J. Pharm. 310(1-2): 2006 154-161.
27. Guggi D, Kast CE, Bernkop-Schnurch A. In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm. Res. 2003;20(12): 1989-1994.
28. Hombach J, Hoyer H, Bernkop-Schnurch A. Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system. Eur. J. Pharm. Sci. 2008;33 (1):1-8.
29. Krauland AH, Guggi D, Bernkop-Schnurch A. Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats. J. Control. Release 2004;95(3): 547-555.
30. Le Tien C, Lacroix M, Ispas-Szabo P, Mateescu MA. N-Acylated chitosan: hydrophobic matrices for controlled drug release. J. Control. Release 2003;93(1):1-13.
31. Mura P, Zerrouk N, Mennini N, Maestrelli F, Chemtob C. Development and characterization of naproxen-chitosan solid systems with improved drug dissolution properties. Eur. J. Pharm. Sci. 2003;19(1):67-75.
32. El-Gibaly I. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. Int. J. Pharm. 2002;249 (1-2):7-21.
33. Fetih G, Fausia H, Okada N, Fujita T, AttiaM, Yamamoto A. Colon-specific delivery and enhanced colonic absorption of [Asu(1,7)]-eel calcitonin using chitosan capsules containing various additives in rats. J. Drug Target. 2006;14(3): 165-172.
34. Fetih G, Lindberg S, Itoh K, Okada N, Fujita T, Habib F, et al. Improvement of absorption enhancing effects of n-dodecylbeta- D-maltopyranoside by its colon-specific delivery using chitosan capsules. Int. J. Pharm. 2005;293(1-2): 127-135.
35. Margulis EB, Moustafine RI. Swellability testing of chitosan/ Eudragit L100-55 interpolyelectrolyte complexes for colonic drug delivery. J. Control. Release 2006; 28; 116(2):e36-e37.
36. McConnell EL, Murdan S, BasitAW.An investigation into the digestion of chitosan (noncrosslinked and crosslinked) by human colonic bacteria. J. Pharm. Sci. 2008;97(9): 3820-3829.
37. Park HS, Lee JY, Cho SH, Baek HJ, Lee SJ. Colon delivery of prednisolone based on chitosan coated polysaccharide tablets. Arch. Pharm. Res. 2002;25(6):964-968.
38. Patel M, Shah T, Amin A. Therapeutic opportunities in colonspecific drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 2007;24(2):147-202.
39. Shimono N, Takatori T, Ueda M, Mori M, Higashi Y, Nakamura Y. Chitosan dispersed system for colon-specific drug delivery. Int. J. Pharm. 2002;245(1-2):45-54.
40. Simonoska Crcarevska M, Glavas Dodov M, Goracinova K. Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. Eur. J. Pharm. Biopharm. 2008;68(3):565-578.
41. Smoum R, Rubinstein A, Srebnik M. Chitosan-pentaglycine- phenylboronic acid conjugate: a potential colon-specific platform for calcitonin. Bioconjug. Chem. 2006;17(4): 1000-1007.
42. Tozaki H, Fujita T, Odoriba T, Terabe A, Suzuki T, Tanaka C, et al. Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid- induced ulcerative colitis in rats. Life Sci. 1999; 64(13):1155-1162.
43. Win PP, Shin-ya Y, Hong K-J, Kajiuchi T. Formulation and characterization of pH sensitive drug carrier based on phosphorylated chitosan (PCS). Carbohydr. Polym. 2003;53: 305-310.
44. Tu J, Bolla S, Barr J, Miedema J, Li X, Jasti B. Alginate microparticles prepared by spray-coagulation method: preparation, drug loading and release characterization. Int. J. Pharm. 2005;303(1-2):171-181.
45. Scocca S, Faustini M, Villani S, Munari E, Conte U, Russo V, et al. Alginate/polymethacrylate copolymer microparticles for the intestinal delivery of enzymes. Curr. Drug Deliv. 2007;4 (2):103-108.
46. Greimel A, Werle M, Bernkop-Schnurch A. Oral peptide delivery: in-vitro evaluation of thiolated alginate/poly(acrylic acid) microparticles. J. Pharm. Pharmacol. 2007;59(9): 1191-1198.
47. Rastogi R, Sultana Y, Aqil M, Ali A, Kumar S, Chuttani K, et al. Alginate microspheres of isoniazid for oral sustained drug delivery. Int. J. Pharm. 2007;334(1-2):71-77.
48. Reis CP, Ribeiro AJ, Neufeld RJ, Veiga F. Alginate microparticles as novel carrier for oral insulin delivery. Biotechnol. Bioeng. 2007;96(5):977-989.
49. Coppi G, Iannuccelli V, Sala N, Bondi M. Alginate microparticles for Polymyxin B Peyer's patches uptake: microparticles for antibiotic oral administration. J. Microencapsul. 2004;21(8):829-839.
50. Lawuyi B, Chen H, Afkhami F, Kulamarva A, Prakash S. Microencapsulated engineered Lactococcus lactis cells for heterologous protein delivery: preparation and in vitro analysis. Appl. Biochem. Biotechnol. 2007;142(1):71-80.
51. Simi CK, Emilia Abraham T. Encapsulation of crosslinked subtilisin microcrystals in hydrogel beads for controlled release applications. Eur. J. Pharm. Sci. 2007;32(1):17-23.
52. Abdelkader H, Abdalla OY, Salem H. Formulation of controlled- release baclofen matrix tablets: influence of some hydrophilic polymers on the release rate and in vitro evaluation. AAPS PharmSciTech 2007;8(4):E100.
53. Ajdary S, Dobakhti F, Taghikhani M, Riazi-Rad F, Rafiei S, Rafiee-Tehrani M. Oral administration of BCG encapsulated in alginate microspheres induces strong Th1 response in BALB/c mice. Vaccine 2007;25(23):4595-4601.
54. Cui JH, Cao QR, Lee BJ. Enhanced delivery of bifidobacteria and fecal changes after multiple oral administrations of bifidobacteria- loaded alginate poly-L-lysine microparticles in human volunteers. Drug Deliv. 2007;14(5):265-271.
55. Kim B, Bowersock T, Griebel P, Kidane A, Babiuk LA, Sanchez M, et al. Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres. J. Control. Release 2002;85(1-3):191-202.
56. Al-Kassas RS, Al-Gohary OM, Al-Faadhel MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int. J. Pharm. 2007;341(1-2):230-237.
57. Silva CM, Veiga F, Ribeiro AJ, Zerrouk N, Arnaud P. Effect of chitosan-coated alginate microspheres on the permeability of Caco-2 cell monolayers. Drug Dev. Ind. Pharm. 2006;32 (9):1079-1088.
58. Yegin BA, Moulari B, Durlu-Kandilci NT, Korkusuz P, Pellequer Y, Lamprecht A. Sulindac loaded alginate beads for a mucoprotective and controlled drug release. J. Microencapsul. 2007;24(4):371-382.
59. Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide hydrogels for modified release formulations. J. Control. Release 2007;119(1):5-24.
60. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 2003; 6(1):33-66.
61. Liu L, Fishman ML, Kost J, Hicks KB. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials 2003;24(19):3333-3343.
62. Sande SA. Pectin-based oral drug delivery to the colon. Expert Opin. Drug Deliv. 2005;2(3):441-450.
63. Ofori-Kwakye K, Fell JT, Sharma HL, Smith AM. Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release. Int. J. Pharm. 2004;270(1-2): 307-313.
64. Chambin O, Dupuis G, Champion D, Voilley A, Pourcelot Y. Colon-specific drug delivery: influence of solution reticulation properties upon pectin beads performance. Int. J. Pharm. 2006;321(1-2):86-93.
65. Dupuis G, Chambin O, Genelot C, Champion D, Pourcelot Y. Colonic drug delivery: influence of cross-linking agent on pectin beads properties and role of the shell capsule type. Drug Dev. Ind. Pharm. 2006;32(7):847-855.
66. El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int. J. Pharm. 2002;232(1-2):199-211.
67. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. In-vitro and in-vivo studies of pectin/ethylcellulose film-coated pellets of 5-fluorouracil for colonic targeting. J. Pharm. Pharmacol. 2008;60(1):35-44.
68. Sriamornsak P, Kennedy RA. Development of polysaccharide gel-coated pellets for oral administration: swelling and release behavior of calcium pectinate gel. AAPS PharmSciTech 2007;8(3):E79.
69. Sriamornsak P, Burton MA, Kennedy RA. Development of polysaccharide gel coated pellets for oral administration. 1.Physico-mechanical properties. Int. J. Pharm. 2006;326 (1-2):80-88.
70. Xu C, Zhang JS, Mo Y, Tan RX. Calcium pectinate capsules for colon-specific drug delivery. Drug Dev. Ind. Pharm. 2005;31(2):127-134.
71. Lee JS, Chung D, Lee HG. Preparation and characterization of calcium pectinate gel beads entrapping catechin-loaded liposomes. Int. J. Biol. Macromol. 2008;42(2):178-184.
72. Li CL, Martini LG, Ford JL, Roberts M. The use of hypromellose in oral drug delivery. J. Pharm. Pharmacol. 2005;57 (5):533-546.
73. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, et al. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 2003;92(12):2386-2398.
74. Nunthanid J, Huanbutta K, Luangtana-Anan M, Sriamornsak P, Limmatvapirat S, Puttipipatkhachorn S. Development of time-, pH-, and enzyme-controlled colonic drug delivery using spray-dried chitosan acetate and hydroxypropyl methylcellulose. Eur. J. Pharm. Biopharm. 2008;68(2):253-259.
75. Honkanen O, Laaksonen P, Marvola J, Eerikainen S, Tuominen R, Marvola M. Bioavailability and in vitro oesophageal sticking tendency of hydroxypropyl methylcellulose capsule formulations and corresponding gelatine capsule formulations. Eur. J. Pharm. Sci. 2002;15(5):479-488.
76. Akbari J, Nokhodchi A, Farid D, Adrangui M, Siahi-Shadbad MR, Saeedi M. Development and evaluation of buccoadhesive propranolol hydrochloride tablet formulations: effect of fillers. Farmaco 2004;59(2):155-161.
77. Choi H, Jung J, Yong CS, Rhee C, Lee M, Han J, et al. Formulation and in vivo evaluation of omeprazole buccal adhesive tablet. J. Control. Release 2000;68(3):405-412.
78. Alsarra IA, Alanazi FK, Mahrous GM, Abdel Rahman AA, Al Hezaimi KA. Clinical evaluation of novel buccoadhesive REFERENCES 85 film containing ketorolac in dental and post-oral surgery pain management. Pharmazie 2007;62(10):773-778.
79. Carlo Ceschel G, Bergamante V, Calabrese V, Biserni S, Ronchi C, Fini A. Design and evaluation in vitro of controlled release mucoadhesive tablets containing chlorhexidine. Drug Dev. Ind. Pharm. 2006;32(1):53-61.
80. Hosny EA, Elkheshen SA, Saleh SI. Buccoadhesive tablets for insulin delivery: in-vitro and in-vivo studies. Boll. Chim. Farm. 2002;141(3):210-217.
81. Agarwal V, Mishra B. Design, development, and biopharmaceutical properties of buccoadhesive compacts of pentazocine. Drug Dev. Ind. Pharm. 1999;25(6):701-709.
82. Ali J, Hasan S, Ali M. Formulation and development of gastroretentive drug delivery system for ofloxacin. Methods Find. Exp. Clin. Pharmacol. 2006;28(7):433-439.
83. Harris D, Fell JT, Taylor DC, Lynch J, Sharma HL. Oral availability of a poorly absorbed drug, hydrochlorothiazide, from a bioadhesive formulation in the rat. Int. J. Pharm. 1989;56(2):97-102.
84. McConville JT, Ross AC, Florence AJ, Stevens HN. Erosion characteristics of an erodible tablet incorporated in a timedelayed capsule device. Drug Dev. Ind. Pharm. 2005;31 (1):79-89.
85. Chavanpatil M, Jain P, Chaudhari S, Shear R, Vavia P. Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Int. J. Pharm. 2005;304(1-2):178-184.
86. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int. J. Pharm. 2006;316(1-2):86-92.
87. Baumgartner S, Kristl J, Peppas NA. Network structure of cellulose ethers used in pharmaceutical applications during swelling and at equilibrium. Pharm. Res. 2002;19(8): 1084-1090.
88. Bindschaedler C, Gurny R, Doelker E. Osmotically controlled drug delivery systems produced from organic solutions and aqueous dispersions of cellulose acetate. J. Control. Release 1986;4(3):203-212.
89. Khan MA, Sastry SV, Vaithiyalingam SR, Agarwal V, Nazzal S, Reddy IK. Captopril gastrointestinal therapeutic system coated with cellulose acetate pseudolatex: evaluation of main effects of several formulation variables. Int. J. Pharm. 2000;193(2):147-156.
90. He L, Gong T, Zhao D, Zhang ZR, Li L. A novel controlled porosity osmotic pump system for sodium ferulate. Pharmazie 2006;61(12):1022-1027.
91. Atyabi F, Khodaverdi E, Dinarvand R. Temperature modulated drug permeation through liquid crystal embedded cellulose membranes. Int. J. Pharm. 2007;339(1-2): 213-221.
92. Dabbagh MA, Ford JL, Rubinstein MH, Hogan JE. Effects of polymer particle size, compaction pressure and hydrophilic polymers on drug release from matrices containing ethylcellulose. Int. J. Pharm. 1996;140(1):85-95.
93. Katikaneni PR, Upadrashta SM, Neau SH, Mitra AK. Ethylcellulose matrix controlled release tablets of a watersoluble drug. Int. J. Pharm. 1995;123(1):119-125.
94. Lindstedt B, Sjoberg M, Hjartstam J. Osmotic pumping release from KCl tablets coated with porous and non-porous ethylcellulose. Int. J. Pharm. 1991;67(1):21-27.
95. Majid Khan G, Bi Zhu J. Ibuprofen release kinetics from controlled-release tablets granulated with aqueous polymeric dispersion of ethylcellulose II: influence of several parameters and coexcipients. J. Control. Release 56(1-3): 1998 127-134.
96. George HK, Evone SG, Stuart CP, Joseph BS. Formulation of Controlled Release Matrices by Granulation with a Polymer Dispersion. Drug Dev. Ind. Pharm. 1990;16(9): 1473-1490.
97. Brunner M, Lackner E, Exler PS, Fluiter HC, Kletter K, Tschurlovits M, et al. 5-Aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. Aliment. Pharmacol. Ther. 2006;23(1):137-144.
98. Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGAnanoparticles. Int. J.Pharm. 2006;314(1):72-82.
99. Helliwell M. The use of bioadhesives in targeted delivery within the gastrointestinal tract. Adv. Drug Deliv. Rev. 1993;11(3):221-251.
100. Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev. 2005;57(11):1666-1691.
101. Owens TS, Dansereau RJ, Sakr A. Development and evaluation of extended release bioadhesive sodium fluoride tablets. Int. J. Pharm. 2005;288(1):109-122.
102. Petrovic A, Cvetkoviæ N, Trajkovic S, Ibric S, Popadic D, Djuric Z. Mixture design evaluation of drug release from matrix tablets containing carbomer and HPMC. J. Control. Release 2006;116(2):e104-e106.
103. Tapia-Albarran M,Villafuerte-Robles L. Assay of amoxicillin sustained release from matrix tablets containing different proportions of Carbopol 971P NF. Int. J. Pharm. 2004;273 (1-2):121-127.
104. Bommareddy GS, Paker-Leggs S, Saripella KK, Neau SH. Extruded and spheronized beads containing Carbopol® 974P to deliver nonelectrolytes and salts of weakly basic drugs. Int. J. Pharm. 2006;321(1-2):62-71.
105. Ito R, Machida Y, Sannan T, Nagai T. Magnetic granules: a novel system for specific drug delivery to esophageal mucosa in oral administration. Int. J. Pharm. 1990;61(1-2):109-117.
106. Nagano H, Machida Y, Iwata M, Imada T, Noguchi Y, Matsumoto A, et al. Preparation of magnetic granules containing bleomycin and its evaluation using model esophageal cancer. Int. J. Pharm. 1997;147(1):119-125.
107. Kojima H, Yoshihara K, Sawada T, Kondo H, Sako K. Extended release of a large amount of highly water-soluble diltiazem hydrochloride by utilizing counter polymer in polyethylene oxides (PEO)/polyethylene glycol (PEG) matrix tablets. Eur. J. Pharm. Biopharm. 2008;70(2):556-562.
108. Maggi L, Bruni R, Conte U. High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms. Int. J. Pharm. 2000;195(1-2): 229-238.
109. Maggi L, Segale L, Torre ML, Ochoa Machiste E, Conte U. Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (PEOs) for the controlled release of a water-soluble drug. Dimensionality study. Biomaterials 2002;23(4):1113-1119.
110. Wu N, Wang L-S, Tan DC-W, Moochhala SM, Yang Y-Y. Mathematical modeling and in vitro study of controlled drug release via a highly swellable and dissoluble polymer matrix: polyethylene oxide with high molecular weights. J. Control. Release 2005;102(3):569-581.
111. Mahalingam R, Jasti B, Birudaraj R, Stefanidis D, Killion R, Alfredson T, et al. Evaluation of Polyethylene oxide compacts as gastroretentive delivery systems. AAPS PharmSciTech, published online: January 16 2009.